Clingan P, Ladwa R, Brungs D, et al. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. Journal for ImmunoTherapy of Cancer 2023;11:e007637. doi:10.1136/jitc-2023-00763 (View Journal for ImmunoTherapy of Cancer paper)
Plock, N; Kleijn HJ; Neighbours, L; Oliviero, J. Population Pharmacokinetic Analysis of PD-L1 Checkpoint Inhibitor Cosibelimab in Subjects with Advanced Cancers. Population Approach Group Europe (PAGE) 2023 Annual Meeting. (PAGE 31 (2023) Abstr 10300). (View PAGE 2023 Annual Meeting Poster)
Clingan, P., et al. Efficacy and Safety of Cosibelimab, an Anti–PD-L1 Antibody, in Patients With Metastatic Cutaneous Squamous Cell Carcinoma: Results From Pivotal Cohort. 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. 2022-06-06 Poster 9537. (View ASCO 2022 Annual Meeting Poster)
Harris, D., et al. Cosibelimab, an anti-PD-L1 antibody: Preliminary Safety and Efficacy Results from a Global, Multicohort Phase 1 Clinical Trial. Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting. 2020-11-09 Poster 399. (View SITC 2020 Meeting Poster)
Clingan, P., et al. Cosibelimab, an Anti-PD-L1 Antibody, in Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Preliminary Safety and Efficacy Results from a Phase 1 Clinical Trial. European Society for Medical Oncology (ESMO) Congress. 2020-09-17 Poster 1084P. (View Cosibelimab ESMO 2020 Poster)
Lin, L., et al. Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (cosibelimab) in oncology patients. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. 2019-11-08 Abstract P431 (View SITC 2019 Meeting Poster)
Clingan, P., et al. Safety, Efficacy and Pharmacokinetic Profile of Cosibelimab, an Anti-PD-L1 Antibody, in Patients with Advanced Cancers. European Society for Medical Oncology (ESMO) Congress. 2019-09-28 Poster 469P. (View Cosibelimab ESMO Poster)
Gorelik, L., et al. Preclinical characterization of a novel fully human IgG1 anti-PD-L1 mAb CK-301. American Association for Cancer Research Annual Meeting (AACR). 2016-04-04 Abstract 4606. (View CK-301 AACR Poster)
Johnson, M., et al. CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial. International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer. 2018-09-24 Abstract. (View CK-101 Data Presentation)
Qian, X., et al. CK-101 (RX518), a mutant-selective inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. American Association for Cancer Research Annual Meeting (AACR). 2016-04-03 Abstract 2078. (View CK-101 AACR Poster)
Normant, E., et al. TG-1601 is a novel BET inhibitor with strong binding affinity and long-lasting effect in pre-clinical models. American Association for Cancer Research Annual Meeting (AACR). 2018-04-18 Abstract 5790. (View CK-103 AACR Poster)
Chang, D.-K. et al. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Mol. Cancer 14, 119 (2015).
Xu, C. et al. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One 5, e9625 (2010).